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Major depressive disorder (MDD) is a common psychiatric illness, with 6–12% lifetime prevalence. It is also
among the ﬁve most disabling diseases worldwide. Current pharmacological treatments, although relatively
effective, present important side effects that lead to treatment discontinuation. Therefore, novel treatment
options for MDD are needed. Here, we discuss the recent advancements of one new neuromodulatory
technique – transcranial direct current stimulation (tDCS) – that has undergone intensive research over the
past decade with promising results. tDCS is based on the application of weak, direct electric current over the
scalp, leading to cortical hypo- or hyper-polarization according to the speciﬁed parameters. Recent studies
have shown that tDCS is able to induce potent changes in cortical excitability as well as to elicit long-lasting
changes in brain activity. Moreover, tDCS is a technique with a low rate of reported side effects, relatively easy
to apply and less expensive than other neuromodulatory techniques — appealing characteristics for clinical
use. In the past years, 4 of 6 phase II clinical trials and one recent meta-analysis have shown positive results in
ameliorating depression symptoms. tDCS has some interesting, unique aspects such as noninvasiveness and
low rate of adverse effects, being a putative substitutive/augmentative agent for antidepressant drugs, and
low-cost and portability, making it suitable for use in clinical practice. Still, further phase II and phase III trials
are needed as to better clarify tDCS role in the therapeutic arsenal of MDD.
© 2012 Elsevier Inc. All rights reserved.
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1. Introduction
Major depressive disorder (MDD) is a severe, chronic and prevalent
psychiatric illness, with community-based surveys showing a lifetime
prevalence ranging from 6 to 12%, and an annual prevalence of 3–11%
worldwide (Andrade et al., 2003; Kessler et al., 2005; Waraich et al.,
2004). It is expected to be the second most disabling condition by
2020 (Murray and Lopez, 1997). In addition, nearly 80% of patients re-
lapse after one antidepressant treatment (Anderson et al., 2008) and al-
most 33% of patients fail to achieve remission after two or more
antidepressant trials — a condition named treatment-resistant depres-
sion (Berlim and Turecki, 2007). Moreover, antidepressant side effects
such as weight gain; sexual dysfunction and somnolence can signiﬁ-
cantly decrease patient compliance of maintenance treatment in MDD
(Brunoni et al., 2009; Zajecka, 2000). Therefore, the development of
new therapeutic interventions for the treatment of this psychiatric ill-
ness is needed.
In fact, one ﬁeld under intensive investigation is neuromodulation.
From electroconvulsive therapy (ECT) to novel clinical and preclinical
techniques, such as transcranial magnetic stimulation (TMS), vagus
nerve stimulation (VNS) and transcranial direct current stimulation
(tDCS), these techniques aim to develop novel non-pharmacological
interventions for the treatment of neuropsychiatric disorders.
Neuromodulation can be either invasive, for instance, Deep Brain Stim-
ulation (DBS), a technique that implants electrodes in subcortical areas
aiming the treatment of conditions such as Parkinson's disease and,
more recently, MDD (George and Aston-Jones, 2010); or non-invasive,
such as repetitive transcranial magnetic stimulation (rTMS) and trans-
cranial direct current stimulation (tDCS) (Fig. 1).
RTMS uses a coil positioned over the scalp as to generate a potent,
pulsatile electromagnetic ﬁeld (up to 3 T), secondarily inducing an elec-
tric currentﬂow inside the brain. Conversely, tDCS is based on the appli-
cation ofweak (0.5–2 mA), direct electric current into the brain through
relatively large electrodes placed over the scalp (George and Aston-
Jones, 2010). For MDD, rTMS has been more investigated than tDCS
hitherto, with dozens of phase-II trials and at least two phase-III trials
showing its efﬁcacy — in fact, rTMS has been ultimately approved for
the treatment of MDD by regulatory agencies and is being increasingly
used worldwide (Brunoni et al., 2010). Nevertheless, this technique
has some drawbacks, such as (1) cost: application of rTMS usually
costs US$ 300.00 per session, which is expensive in most settings
(Simpson et al., 2009); (2) clinical applicability: rTMS is a non-
portable device that can be used only in hospital and/or ambulatory set-
tings, obligating patients to perform daily visits to the clinic; (3) avail-
ability: rTMS is a relatively expensive device applied only by trained
physicians. These issues greatly limit rTMS availability (Priori et al.,
2009). One possible solution is developing handheld rTMS devices,
which are in fact currently under investigation (George and Aston-
Jones, 2010). Another solution would be a device that combines the
non-pharmacological advantages of rTMS with low-cost, easiness of
use and portability; in fact, these characteristics are present in tDCS de-
vices. Currently, tDCS research on MDD has experimented signiﬁcant
advancement, with some clinical trial showing promising results
(Boggio et al., 2008a; Brunoni et al., 2011b; Ferrucci et al., 2009b;
Fregni et al., 2006a). The aim of this review is, therefore, to summarize
the main aspects and challenges of tDCS as a novel treatment for major
depression.
2. Historical remarks
Reports of brain stimulation through electric currents have existed
since the Ancient time; with observations by Greek and Roman physi-
cians that the electric “torpedo ﬁsh” delivered electric discharges that
could relieve headache (Largus, 1529). After the introduction of the
electric battery in the 18th century, some physicians started to use
these galvanic batteries to perform electric brain stimulation in selected
subjects (Zago et al., 2008), although these interventions were uncon-
trolled and received with skepticism by academics of the epoch. In
fact, controlled, systematic research using brain electric stimulation
only began in the 1950s and 1960s with the classic studies of Purpura
and McMurtry and Bindman and colleagues, who showed in experi-
mental animals that anodal and cathodal cortical stimulation could in-
crease and decrease cortical activity, respectively (Bindman et al.,
1964; Purpura and McMurtry, 1965). During 1964–1974 a few clinical
trials using tDCS for MDD were also conducted, although with overall
mixed results (Nitsche et al., 2009a). However, during the 1970s and
1980s tDCS research faded, possibly due to the advancement and initial-
ly positive results of psychopharmacology. The technique of tDCS was
only reappraised at the turn of this century, with the seminal studies
of Priori et al. (1998) followed by Nitsche and Paulus (2000) who
showed that DC stimulation delivered transcranially could modify cor-
tical excitability in a polarity-dependent and intensity-dependentman-
ner. From then onwards, several studies investigated tDCS in basic and
applied research, using this technique either as a tool to investigate spe-
ciﬁc cortical brain areas or as a novel treatment for neuropsychiatric dis-
orders (Brunoni et al., 2011d).
3. Technical aspects and mechanisms of action
tDCS devices are essentially composed by four main components:
electrodes (usually one anode and one cathode), power supply (usually
9 V batteries), an amperemeter (formeasurement of the intensity of the
electric current) and a potentiometer (to allow adjustment of the elec-
tric current). One electrode is necessarily placed over the scalp, above
the cortical area aimed to be stimulated. The other electrode can be
also positioned over the scalp, or, alternatively, on an extra-cephalic po-
sition (e.g., deltoid muscle). For MDD, the anode is placed over the area
corresponding to the left dorsolateral prefrontal cortex (F3 according to
the EEG 10/20 system). Twomain protocols are used regarding cathode
placement: one places it over the right dorsolateral prefrontal cortex
Fig. 1. The biological therapies for the treatment of major depressive disorder.rTMS =
repetitive transcranial magnetic stimulation; tDCS = transcranial direct current stimu-
lation; VNS = vagus nerve stimulation; ECT = electroconvulsive therapy; DBS = deep
brain stimulation.
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(F4 area) and the other, over the left supraorbital region (F8 area). The
former strategy takes advantage of the prefrontal cortex asymmetry
theory forMDD (discussed later), aiming to restore the left-to-right im-
balance to “normal” activity. The rationale for the second strategy is that
most studies consider the F8 area as neutral or at least less critical given
tDCSmodulation, therefore assuming any physiological or clinical effect
solely due to the anodal stimulation over F3. However, this assumption
is not necessarily true, for instance, studies using simulated models
show that there is brain activation in the areas beneath the cathode
(Miranda et al., 2006). Also in Boggio et al. (2008a) study, when authors
changed the DLPFC electrode to the occipital area but kept the supraor-
bital (F8) electrode, it induced a larger effect compared to sham stimu-
lation, although this strategy was associated with smaller effects than
the DLPFC-supraorbital montage (Fig. 2).
When tDCS is turned on, a weak (0.5–2 mA) and direct electric
current ﬂows from the anode (positive pole) to the cathode (negative
pole). As a result, brain areas close to the anode become hypo-
polarized and those near to the cathode are hyper-polarized. It is im-
portant to underscore that tDCS per se does not trigger action poten-
tials (this is one fundamental difference between this technique and
rTMS); rather, it facilitates or inhibits spontaneous neuronal network
activity — thus tDCS is more properly considered a neuromodulatory
(instead of a neurostimulation) technique (Priori et al., 2009). This is
because the membrane potentials are hyperpolarized or depolarized
by only a few mV with the electric currents applied in tDCS protocols,
which is much lower than the necessary threshold for eliciting action
potentials: for instance, a 2 mA current can change the membrane
potential in approximately 0.8 mV, whereas at least 20 mV is neces-
sary to trigger action potentials (Ruohonen and Karhu, 2012). In fact,
tDCS might act on spike timing, modulating net cortical excitability
(Radman et al., 2009).
In addition, tDCS can also induce effects beyond the period of
stimulation (a single session can generate long-lasting effects for up
to 90 min) (Brunoni et al., 2011d). This indicates that tDCS not only
changes neuronal membrane potential but also induces synaptic
changes. In fact, studies using tDCS coupled with NMDA-antagonist
drugs showed abolishment of tDCS after-effects, whereas association
of tDCS with NMDA-agonists enhanced its aftereffects (Nitsche et al.,
2003, 2004). As NMDA receptors are post-synaptic glutamatergic re-
ceptors that play a critical role in long-term potentiation (LTP) and
synaptic strengthening, this evidence endorses tDCS as a promising
tool to induce neuroplasticity. Moreover, monoaminergic drugs also
modify tDCS effects — for instance, citalopram, a SSRI (selective sero-
tonin reuptake inhibitor) enhances anodal tDCS effects, pergolide
(a dopamine agonist) enhances cathodal tDCS effects, amphetamines
enhance anodal tDCS effects and sulpiride (a post-synaptic dopamine
blocker) abolishes tDCS effects (Stagg and Nitsche, 2011).
4. tDCS for major depressive disorder
4.1. Putative mechanisms of action
Among several biological hypotheses for explaining MDD, one
specially appealing to the ﬁeld of neuromodulation is the neural sys-
tem hypothesis, which understands depression as a condition relat-
ed to dysfunction in several cortical and subcortical areas, specially
(as shown by neuroimaging and EEG studies) the dorsolateral and
ventromedial areas of the prefrontal cortex (PFC), the amygdala
and the hippocampus (Campbell et al., 2004; Hamilton et al.,
2008), which are associatedwith symptoms such as psychomotor re-
tardation and executive dysfunction (related to PFC) as well as anhe-
donia and feelings of guilt and hopelessness (related to subcortical
areas) (Brunoni et al., 2010). Moreover, patients with MDD have
interhemispheric imbalance, with lower activity in the left hemi-
sphere and higher activity in the right cortex. This functional asym-
metry is supposed to be related to differential emotional judgment
towards negative aspects (Vanderhasselt et al., 2009). This neural
system hypothesis also agrees with classic observations of MDD
being related to monoaminergic deﬁciencies and a hyperactive
hypothalamic-pituitary-adrenal (HPA) axis. The monoamine hypothe-
sis is based on pharmacological studies that show that tricyclics and
SSRIs are effective for depression. In fact, noradrenergic, serotoninergic
and dopaminergic neurons project from subcortical regions such as the
locus ceruleus, raphenuclei and the nucleus accumbens, respectively, to
cortical areas, especially the PFC. Thus, monoaminergic impairment
consequently results in cortical–subcortical dysfunction. The HPA
hyperactivation is another classic observation in MDD studies during
the 1980s. In fact, as higher cortical areas modulate the HPA system,
dysfunction of the cortical–subcortical system is also reﬂected in greater
HPA activity.
According to these frameworks, the aim of anodal simulation over
the left dorsolateral PFC is to increase cortical activity in this area.
Neuropsychological studies modulating the left dorsolateral PFC
showed an improvement of executive functioning in working memo-
ry tests as well as enhancement of identiﬁcation of positive visual ma-
terial (Boggio et al., 2009; Fregni et al., 2005). Daily, repeated tDCS
sessions are, thus, supposed to modulate this cortical area and also,
via top-down modulation, other subcortical areas. For instance, Beeli
et al. (2008) used cathodal tDCS over the right PFC in a visual task,
achieving modulation of skin conductance, thus indicating indirect
tDCS modulation of subcortical areas.
Besides left dorsolateral PFC stimulation and top-down modulation,
tDCS could also act in depression via “left-to-right” modulation — i.e.,
using the anode electrode over the left PFC and the cathode electrode
over the right PFC. In this “bifrontal” setup, one aims to simultaneously
enhance left PFC activity, as anodal stimulation increases spontaneous
neural activity, while right PFC activity is inhibited as cathodal stimula-
tion decreases neural activity (Ferrucci et al., 2009b).
Lastly, the LTP-deﬁciency hypothesis of depression proposes that
focal deﬁcits in neuroplasticity in certain brain areas could be the ﬁnal
common pathway underlying the clinical and biological characteristics
of depression. For instance, depressed subjects present deﬁcits in de-
clarative memory consolidation, enhanced fear acquisition and im-
paired visual discrimination, suggesting deﬁcits in LTP mechanisms in
the hippocampus, amygdala and the visual system (Nissen et al.,
2010; Normann et al., 2007) and in addition, overall decreased levels
of BDNF (Brunoni et al., 2008). Moreover, a chronic-stress, animal
model of depression showed that the antidepressant ﬂuvoxamine
prevented the facilitation of long-term depression (LTD) and it also in-
creased LTP in the hippocampus, corroborating this hypothesis. Inter-
estingly, an animal study using direct current stimulation showed that
this technique induces BDNF-dependent synaptic plasticity (Fritsch et
al., 2010) and studies exploring the electrophysiology of tDCS also dem-
onstrate that tDCS induces neuroplasticity (Stagg and Nitsche, 2011).
Fig. 2. Montage of transcranial direct current stimulation.The ﬁgures show the main
montages used for major depression: in both, the anode is positioned over the left dor-
solateral prefrontal cortex. The cathode can be either placed over the right dorsolateral
prefrontal cortex (ﬁgure A) or the right supraorbital area (ﬁgure B).
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Therefore, another putative mechanism of action for tDCS would be to
induce neuroplasticity that is impaired in depression.
4.2. Empirical evidence from rTMS
Another bulk of evidence comes from the almost ﬁfty randomized
controlled trials conducted using rTMS as a treatment for MDD. Two
recent meta-analyses showed that either high-frequency, left or
low-frequency or right dorsolateral PFC stimulation is an effective an-
tidepressant strategy (Schutter, 2009, 2010). This framework can be
transposed to tDCS, since anodal stimulation increases whereas cath-
odal decreases cortical excitability, analogously to high-frequency
and low-frequency stimulation, respectively.
4.3. Preclinical studies
Although available animal tDCS studies did not speciﬁcally evaluate
experimental models for depression, they provide interesting insights.
For instance, two studies in healthy Sprague–Dawley rats used active an-
odal tDCS over the rat cortex as to evaluate functional magnetic reso-
nance imaging (Takano et al., 2011) and cerebral blood ﬂow (Wachter
et al., 2011) changes before and after stimulation. The studies observed
an increase in brain activity and blood ﬂow, respectively. Likewise, ex-
perimental animal studies also showed that cathodal stimulation de-
creased cerebral blood ﬂow (Wachter et al., 2011) and reduced pain
(Nekhendzy et al., 2004). These studies demonstrated the polarity-
dependent effects of tDCS and therefore further support “bifrontal”
montages in MDD aiming for simultaneous, differential brain activa-
tion (for a review of tDCS animal studies see (Brunoni et al., 2011c)).
4.4. Relevant ﬁndings in studies with healthy volunteers
Several studies in healthy volunteers support the notion that tDCS
modiﬁes brain activity. One class of studies used TMS as a tool to index
cortical excitability, showing a modulation of the motor-evoked poten-
tials and/or intracortical excitability (Brunoni et al., 2011d; Nitsche et
al., 2005).
Particularly considering the stimulation of the left dorsolateral PFC,
various tDCS studies have shown interesting results. For instance,
Fregni et al. (2005) evaluated working memory using a 3-back test
(a neuropsychological test in which the subject should identify the
same target – usually a letter – that was presented 3 positions earlier)
in 15 healthy volunteers. Those that received active tDCS presented a
higher number of correct responses and also fewer errors. Another
study using the same experiment in patients with Parkinson's disease
presented similar results (Boggio et al., 2006). In addition, Fregni et al.
(2006b) evaluated cognitive functioning using several tests (Mini-
Mental Status Examination, digit span, Stroop test, symbol digits and
ﬁve-point test) in patients with depression, showing increased perfor-
mance in all assessed domains after 5 sessions of anodal tDCS stimula-
tion over the left dorsolateral PFC. The ﬁndings of these studies are
interesting for depression for two reasons: ﬁrst, as MDD is related to
executive impairment, tDCS could be used to restore cognitive deﬁcits
in these patients; second, since dorsolateral PFC activity is both linked
toMDD andworkingmemory, these studies serve as an index of dorso-
lateral PFCmodulation, thus providing further evidence for tDCS clinical
trials on MDD.
Transcranial DC stimulation over the left dorsolateral PFC can also
modulate cognitive functioning. For instance, Kincses et al. (2004)
used the “probabilistic classiﬁcation learning” test that evaluates im-
plicit learning. They showed that anodal tDCS over the left dorsolateral
prefrontal cortex (but not over the occipital cortex or cathodal stimula-
tion) improved performance in this test, in contrast to sham and cath-
odal stimulation. Also, Boggio et al. (2008b) used a go/no-go affective
visual test in subjects receiving active or sham tDCS, ﬁnding that those
receiving active anodal stimulation presented better outcomes.
Therefore, as MDD is related to impairment in affective processing,
tDCS could be used to restore normal affective processing as well as a
putative tool for treating depression.
Recently, neuroimaging studies have been used to determine tDCS
effects. Rango et al. (2008) used proton magnetic resonance spectros-
copy to evaluate brain activity after active or sham tDCS in 10 healthy
volunteers. They showed that only active tDCS was associated with an
increased myoinositol production. They observed that active tDCS in-
creased brain phospholipid metabolism. Also, Lang et al. (2005) used
a PET-scan to show increased rest blood cerebral ﬂow after active an-
odal tDCS. However, Antal et al. (2011) measured BOLD activity
(using functional magnetic resonance imaging) during anodal tDCS
stimulation and a ﬁnger-tapping test, observing paradoxically de-
creasing of BOLD activity during the task.
5. Clinical studies
From 2006 onwards, at least 19 clinical studies with different
methodologies (such as case reports; open-label trials; randomized,
controlled trials; and meta-analysis) have been published exploring
tDCS effects on depression (Table 1). We further discuss their main
ﬁndings and limitations.
5.1. Randomized clinical trials
Fregni et al. (2006a) were the ﬁrst of the “present era” of tDCS
(i.e., apart from the earlier trials conducted from 1964 to 1974) to
show that tDCS could have antidepressant properties. In a pilot ran-
domized, sham-controlled, double-blind trial, 10 patients with mild
to moderate depression and medication free were randomly assigned
to receive either 5 days of active or sham stimulation. They showed
positive results with an improvement of 60% in the active vs. only
12% in the sham group. Fregni et al. (2006b), in another randomized
clinical trial, used the same tDCS protocol with 18 depressed subjects
who were also medication free for 3-months, also ﬁnding signiﬁcant
improvement in the active vs. sham group (58.5% vs. 13.1%, respec-
tively). Later on, Boggio et al. (2008a) enrolled 40 MDD subjects
with different degrees of refractoriness (but medication-free) and
randomized them to 10 sessions of active dorsolateral prefrontal cor-
tex tDCS, active occipital tDCS or sham tDCS. They found that the ac-
tive DLPFC tDCS group presented a superior, signiﬁcant improvement
in HDRS scores compared with the other groups (improvement of
40% in active left PFC vs. 20% in the occipital group and 10% in the
sham group).
Nonetheless, Loo et al. (2010) and Palm et al. (2011) reported dis-
crepant ﬁndings. The ﬁrst group enrolled 40 patients with severe
MDD, in a double-blinded, sham-controlled study but failed to demon-
strate signiﬁcant difference between groups in this phase (similar im-
provements of approximately 19%); tDCS was only more effective
during the open-label phase in which patients received additional ﬁve
sessions. However, this study had some limitations: the dose applied
was relatively low (1 mA), and only ﬁve stimulation sessions were
held, which were alternated, i.e., performed every other day (or second
daily), whereas other studies used consecutive sessions (except for the
ﬁrst pilot study that included patients with mild to moderate depres-
sion (Fregni et al., 2006a)). Moreover, patients with axis II disorders
were excluded, an issue that could have increased sample heterogene-
ity. Palm et al. (2011) randomized 22 patients to receive 1 or 2 mA for
20 min/day per 2 weeks, in a cross-over trial, observing that the groups
were not superior to sham stimulation (14.6%, 16.7% and 9%, for 1 mA,
2 mA and sham, respectively). The authors considered that possible rea-
sons for this ﬁnding were the high degree of treatment-resistance and
the concomitant use of antidepressant medications. In the most recent
randomized, controlled trial published hitherto, Loo et al. (2012), in con-
trast with their previous study, found positive results in a larger trial
with 64 patients that were randomized to receive 3-week active or
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shamanodal tDCS (2 mA/20 min), showing an improvement of 28.4% in
the active group vs. 15.9% in the sham group. In this trial, the sample
was composed of bipolar and unipolar depressed patients, mostly
(67%) on antidepressant treatment and with chronic, treatment-
resistant depression.
Kalu et al. (2012) performed a meta-analysis of these studies,
showing an effect size of 0.74 (95% Conﬁdence Interval 0.21–1.27) fa-
voring the active vs. sham group; therefore suggesting that tDCS in-
deed has antidepressant effects. On the other hand, these authors
also stated that study results differed more than expected by chance,
which was suggestive of between-sample heterogeneity. Interesting-
ly, as seen in Table 1, tDCS protocols can be considered quite homoge-
neous, since all studies performed anodal stimulation over F3 with
the cathode over the right supraorbital cortex. All studies used cur-
rent densities of 0.57 A/m2 (although Palm et al. (2011) also stimulat-
ed with 0.28 A/m2), and all sessions lasted 20 min each. Therefore,
the different results are probably related to the number of sessions,
which ranged from 5 to 15 (although there is no clear number-of-
sessions/response relationship), relatively small sample sizes (which
increase false-positive and false-negative ﬁndings), and sample het-
erogeneity — for instance, Fregni et al. (2006b) and Boggio et al.
(2008a) enrolled medication-free samples whereas Loo et al. (2010)
and Palm et al. (2011) did not. Future phase II trials could have
their designs optimized by adopting stricter eligibility criteria and
could also test different tDCS parameters regarding, for example,
electrode placement, current density and number of sessions. In addi-
tion, alternative clinical trial designs such as select-drop design may
allow investigation of a wider range of parameters.
Nevertheless, further phase III tDCS is also warranted, investigat-
ing tDCS efﬁcacy for MDD in larger samples. Along these lines,
Brunoni et al. (2011e) are conducting an ongoing 2×2 factorial
study in which 120 patients with MDD are being enrolled and ran-
domized to receive tDCS, sertraline, both interventions in combina-
tion or double-placebo, in a factorial design. The results of this
study combined with others will provide more deﬁnite conclusions
regarding the efﬁcacy of tDCS for MDD.
5.2. Open-label studies and case reports
Some non-randomized, open-label studies have also investigated
tDCS effects in MDD. Ferrucci et al. (2009b) stimulated 14 patients with
severe MDD using 2 mA for 20 min for 5 days twice a day (total 10
Table 1
Summary of transcranial direct current stimulation clinical studies for major depressive disorder.
Author Protocol Improvement (change in scores)
Sample size Depression
scale
A C Current
density
(A/m2)
Session
duration
(min)
Number
of
sessions
Frequency Active Control Endpoint
(from 1stday
of treatment)
Randomized, double-blind, controlled trials
Fregni et al. (2006a) 10 HDRS F3 R SO 0.28 20 5 Every other weekday 60% 12% 2 weeks
Fregni et al. (2006b) 18 HDRS F3 R SO 0.28 20 5 Every other weekday 58.50% 13.10% 2 weeks
Boggio et al. (2008a) 40 HDRS F3 R SO 0.57 20 10 Consecutive weekdays 40.40% 10.40% 6 weeks
Loo et al. (2010) 40 MADRS F3 R SO 0.28 20 5 Every other weekday 19.50% 19.20% 2 weeks
Palm et al. (2011) 22 HDRS F3 R SO 0.28/ 0.57 20 10 Consecutive weekdays 14.6%/16.7% 9% 2 weeks
Loo et al. (2012) 64 MADRS F3 R SO 0.57 20 15 Consecutive weekdays 28.40% 15.90% 2 weeks
Open-label studies
Ferrucci et al. (2009b) 14 HDRS/BDI F3 F4 0.57 20 10 2×/day (one weekday) 32.10% – 5 weeks
Ferrucci et al. (2009a) 32 HDRS/BDI F3 F4 0.57 20 10 2×/day (one weekday) 27.70% – 5 weeks
Brunoni et al. (2011b) 31 HDRS/BDI F3 F4 0.57 20 10 2×/day (one weekday) 45.2%(*) – 5 weeks
Dell'osso et al. (2011) 23 HDRS/MADRS F3 F4 0.57 20 10 2×/day (one weekday) 31.30% – 2 weeks
Martin et al. (2011) 11 MADRS F3 R arm 0.57 20 20 Consecutive weekdays 43.80% – 4 weeks
Case reports
Comment
Palm et al. (2009) 1 HDRS/BDI F3 R SO 0.28 20 16 Consecutive weekdays Treatment-resistant depression
modestly improved after tDCS
Arul-Anandam et al. (2010) 1 MADRS F3 R SO 0.28 20 5 Consecutive weekdays Transient hypomania episode that
started after 3-sessions and
resolved spontaneously
Baccaro et al. (2010) 1 YMRS F3 F4 0.8 30 10 Consecutive weekdays Transient hypomania episode that
started after 6-sessions and resolved
spontaneously
Brunoni et al. (2011f) 1 YMRS F3 F4 0.8 30 6 Consecutive weekdays Full-blown manic episode after 6-
sessions of tDCS+sertraline requir-
ing pharmacological intervention
Bueno et al. (2011) 1 MADRS F3 F4 0.8 30 10 Consecutive weekdays Post-stroke depression that markedly
improved after tDCS
Galvez et al. (2011) 1 MADRS F3 R arm 0.57 20 20 2×/day (one weekday) Hypomanic episode in a bipolar
depressed patient after
frontoextracephalic tDCS
Others
Rigonatti et al. (2008) 11 HDRS F3 R SO 0.57 20 10 Consecutive weekdays tDCS and ﬂuoxetine had similar
improvement rates at endpoint, tDCS
was superior at 2 weeks
Kalu et al. (2012) 176 Effect Size of
Depression Scales
F3 R SO 0.28/ 0.57 20 5/10/15 Daily/every other day The ﬁrst tDCS meta-analysis showed
an ES of 0.74 favoring active vs. sham
group although between-sample
heterogeneity was important
HDRS, Hamilton Depression Rating Scale, MADRS, Montgomery-Asberg Depression Rating Scale; YMRS, YoungMania Rating Scale; BDI, Beck Depression Inventory; A, anode; C, cathode;
F3, left dorsolateral prefrontal cortex; F4, right dorsolateral prefrontal cortex; R SO, right supraorbital area; R arm, right arm; ES, effect size. (*) Improvement in bipolar depression group.
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sessions), showing 32.1% depression improvement in 5 weeks. In another
study with 32 patients, Ferrucci et al. (2009a) used the same tDCS proto-
col and observed a similar (27.7%) improvement. In this study, the effects
seemed to bemore robust inmore severe patients. Later on, Brunoni et al.
(2011b) showed that the same protocol was effective in bipolar patients,
with 45% improvement in 5 weeks. Finally, Dell'osso et al. (2011), also
using the same tDCS protocol, observed 31.3% improvement after
5 weeks of treatment onset in 23 patients with refractory depression.
All the abovementioned studies also employed a particular tDCSmontage
inwhich the anode is placed over F3 and the cathode over F4. Theoretical-
ly, this could be a better strategy as some studies suggest that subjects
with depression may exhibit prefrontal cortex asymmetry (hyper-
activation on the right and hypoactivation on the left prefrontal cortex
(Koenigs and Grafman, 2009)) and therefore, this protocol can act simul-
taneously in both areas. In contrast to these studies, Martin et al. (2011)
performed frontal-extracephalic stimulation, i.e., anode over F3 and cath-
ode in an extracephalic position (in this case, the right arm) in 11 patients
with depression, with positive results (43.8% improvement after 4 weeks
of dailyweekday stimulation, total of 20 sessions). In fact, open-label trials
also act as proof-of-concept studies, being useful to test new tDCS proto-
cols, especially when there is no ethical approval to perform sham-
controlled trials, though it is debatable whether there is enough evidence
to rule out equipoise of a tDCS trial using a sham tDCS group as a control.
Also, Rigonatti et al. (2008) performed an open-label follow-up
study in a similar population but testing ﬂuoxetine 20 mg/d for 6-
weeks and comparing with 10 weekday sessions of active tDCS (from
patients of Boggio's study). They observed similar depression improve-
ment at 6 weeks, although tDCS showed superior improvement than
ﬂuoxetine at 2 weeks.
Four of 6 case reports described episodes of treatment-emergent
(hypo)mania. Three cases (Arul-Anandam et al., 2010; Baccaro et al.,
2010; Galvez et al., 2011) reported hypomanic episodes that were
generally benign and directly associated with the tDCS course.
Brunoni et al. (2011f), however, described a severe manic, psychotic
episode after 6 treatment days concomitant use of tDCS and sertraline
that required pharmacological intervention. The other two cases de-
scribed tDCS effects in special situations: Bueno et al. (2011) reported
dramatically improvement of a woman with post-stroke depression
after tDCS whereas Palm et al. (2009) described moderate depression
improvement and signiﬁcant cognitive improvement in a patient
with treatment-resistant depression. These case reports are useful
as they highlight the occurrence of side effects (notably, mania) and
tDCS antidepressant effects in different populations, therefore gener-
ating hypotheses for new studies.
5.3. Safety and tolerance
One recent animal safety study has showed that current parameters
used in clinical studies are probably safe, since brain lesions were only
experimentally induced when rats received cathodal tDCS stimulation
almost one hundred times higher than being used in clinical studies
(Liebetanz et al., 2009). Likewise, a recent review did not observe seri-
ous adverse effects associated with tDCS (Brunoni et al., 2011a). None-
theless, most studies only applied single-sessions of tDCS in healthy
volunteers, whereas clinical use of tDCS involves repeated, daily tDCS
sessions. Such stimulation protocol might induce adverse effects associ-
ated either with daily stimulation, for instance, skin irritation and skin
burn (Palm et al., 2008) or with the disorder — e.g., hypomanic switch
(Arul-Anandam et al., 2010; Baccaro et al., 2010; Brunoni et al., 2011f)
or paradoxical depression worsening.
Still, mild adverse effects of tDCS are relatively common, such as tin-
gling, burning and itching sensations over the electrode site (Brunoni et
al., 2011a). Such effects can be greatly attenuated using sponges embed-
ded with saline (15 to 140 mM) solutions and/or anesthetic creams
(Brunoni et al., 2011d; Nitsche et al., 2008). Nevertheless, future re-
search should still inquire for adverse effects during tDCS sessions.
6. Future directions
Although the abovementioned results are promising, there are im-
portant issues related to tDCS clinical research. We discuss three of
them.
6.1. tDCS and pharmacotherapy
One important issue is the association of tDCS with pharmacother-
apy. Pharmacological studies have shown that drugs can not only en-
hance but also abolish tDCS effects (Brunoni et al., 2011g; Stagg and
Nitsche, 2011). Although this evidence comes from preliminary,
single-session tDCS studies that stimulated the motor cortex (not
the PFC) of healthy volunteers, it is important to investigate whether
and which drug therapies could modify tDCS effects, specially consid-
ering that patients with MDD commonly use a plethora of medicines
of different classes, such as antidepressants, anti-epileptics, anti-
psychotics, lithium and benzodiazepines. In fact, it is unknown how
tDCS effects are modiﬁed by chronic use of psychopharmacological
drugs, an issue to be resolved when applying tDCS in clinical settings.
Remarkably, Nitsche et al. (2009b) explored the effects of citalopram
on tDCS-induced plasticity. After a single dose of 20 mg citalopram or
placebo, they measured motor cortical excitability before and after
anodal or cathodal tDCS, in healthy volunteers. They observed that
citalopram enhanced and prolonged the facilitation induced by anod-
al tDCS whereas it turned cathodal tDCS inhibition into facilitation.
Therefore, it would be interesting to explore whether antidepressant
effects of tDCS combined with antidepressants (particularly seroto-
ninergic) are augmented.
6.2. tDCS and easiness of use
As mentioned earlier, tDCS is less expensive and user-friendlier
than rTMS. Still, it requires daily 20–40 min sessions for 5 to
15 days, demanding frequent visits to the clinic center, which might
be cumbersome and lead to treatment discontinuation. One interest-
ing alternative could be the manufacture of portable tDCS devices
that would allow home application of tDCS after training the patient
how to use it (using tailored head caps could help the patient to
place the electrodes only at the correct spots).
6.3. tDCS and long-term follow-up
A third issue is how tDCS should be used after achieving remission—
i.e., as a maintenance treatment. With pharmacotherapy, this succeeds
immediately after the remission, usually maintaining the same drug
dosage for several months. In non-invasive neuromodulation therapies,
however, the maintenance treatment is still under dispute. Long-term
treatment rTMS studies have followed patients who achieved remission
and thereafter used antidepressant drugs as a maintenance treatment;
using rTMS as an adjuvant, rescue therapy (Demirtas-Tatlidede et al.,
2008). Another alternative would be to maintain frequent (e.g. weekly
or bi-weekly) rTMS sessions during the remission phase. Although
such approach would theoretically avoid depression relapse, it has not
been sufﬁciently investigated (Li et al., 2004). Both alternatives could
be interesting strategies for prospective, long-term tDCS studies.
7. Conclusion
tDCS has a wide range of potential applications, including treat-
ment of major depressive disorder, as preclinical and clinical studies
showed that it elicits potent neuromodulatory effects. tDCS has
some interesting, unique aspects such as noninvasiveness and low
rate of side effects, being a putative substitutive/augmentative agent
for antidepressant drugs, and low-cost and portability, making it suit-
able for use in clinical practice.
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